PURPOSE: This phase II study was designed to determine the overall survival time of adults with supratentorial glioblastoma treated with the immune modulator, polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC), in combination with and following radiation therapy (RT). METHODS AND MATERIALS: This was an open-label, single arm phase II study. Patients were treated with RT in combination with poly-ICLC followed by poly-ICLC as a single agent. Poly-ICLC was initiated 7-28 days after the surgical procedure that established the diagnosis; radiotherapy began within 7 days of the first dose of poly-ICLC and within 35 days of surgical diagnosis. Treatment with poly-ICLC continued following the completion of RT to a maximum of 1 year or until tumor progression. RESULTS: 31 patients were enrolled in this study. One patient did not have a Glioblastoma mutiforme and was deemed ineligible. For the 30 eligible patients, time to progression was known for 27 patients and 3 were censored. The estimated 6-month progression-free survival was 30% and the estimated 1-year progression-free survival was 5%. Median time to progression was as 18 weeks. The 1-year survival was 69% and the median survival was 65 weeks. CONCLUSIONS: The combined therapy was relatively well-tolerated. This study suggests a survival advantage compared to historical studies using RT without chemotherapy but no survival advantage compared to RT with adjuvant nitrosourea or non-temozolomide chemotherapy. Our results suggest that poly-ICLC has activity against glioblastoma and may be worth further study in combination with agents such as temozolomide.
PURPOSE: This phase II study was designed to determine the overall survival time of adults with supratentorial glioblastoma treated with the immune modulator, polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC), in combination with and following radiation therapy (RT). METHODS AND MATERIALS: This was an open-label, single arm phase II study. Patients were treated with RT in combination with poly-ICLC followed by poly-ICLC as a single agent. Poly-ICLC was initiated 7-28 days after the surgical procedure that established the diagnosis; radiotherapy began within 7 days of the first dose of poly-ICLC and within 35 days of surgical diagnosis. Treatment with poly-ICLC continued following the completion of RT to a maximum of 1 year or until tumor progression. RESULTS: 31 patients were enrolled in this study. One patient did not have a Glioblastoma mutiforme and was deemed ineligible. For the 30 eligible patients, time to progression was known for 27 patients and 3 were censored. The estimated 6-month progression-free survival was 30% and the estimated 1-year progression-free survival was 5%. Median time to progression was as 18 weeks. The 1-year survival was 69% and the median survival was 65 weeks. CONCLUSIONS: The combined therapy was relatively well-tolerated. This study suggests a survival advantage compared to historical studies using RT without chemotherapy but no survival advantage compared to RT with adjuvant nitrosourea or non-temozolomide chemotherapy. Our results suggest that poly-ICLC has activity against glioblastoma and may be worth further study in combination with agents such as temozolomide.
Authors: W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch Journal: J Natl Cancer Inst Date: 1993-05-05 Impact factor: 13.506
Authors: J E Talmadge; J Adams; H Phillips; M Collins; B Lenz; M Schneider; E Schlick; R Ruffmann; R H Wiltrout; M A Chirigos Journal: Cancer Res Date: 1985-03 Impact factor: 12.701
Authors: Mitsugu Fujita; Michael E Scheurer; Stacy A Decker; Heather A McDonald; Gary Kohanbash; Edward R Kastenhuber; Hisashi Kato; Melissa L Bondy; John R Ohlfest; Hideho Okada Journal: Clin Cancer Res Date: 2010-05-14 Impact factor: 12.531
Authors: Aaron P Rapoport; Nicole A Aqui; Edward A Stadtmauer; Dan T Vogl; Yin Yan Xu; Michael Kalos; Ling Cai; Hong-Bin Fang; Brendan M Weiss; Ashraf Badros; Saul Yanovich; Gorgun Akpek; Patricia Tsao; Alan Cross; Dean Mann; Sunita Philip; Naseem Kerr; Andrea Brennan; Zhaohui Zheng; Kathleen Ruehle; Todd Milliron; Scott E Strome; Andres M Salazar; Bruce L Levine; Carl H June Journal: Clin Cancer Res Date: 2014-02-11 Impact factor: 12.531
Authors: Xiomara Mercado-López; Christopher R Cotter; Won-Keun Kim; Yan Sun; Luis Muñoz; Karla Tapia; Carolina B López Journal: Vaccine Date: 2013-10-05 Impact factor: 3.641
Authors: Ian F Pollack; Regina I Jakacki; Lisa H Butterfield; Ronald L Hamilton; Ashok Panigrahy; Daniel P Normolle; Angela K Connelly; Sharon Dibridge; Gary Mason; Theresa L Whiteside; Hideho Okada Journal: J Neurooncol Date: 2016-09-13 Impact factor: 4.130
Authors: Panagiotis Vagenas; Meropi Aravantinou; Vennansha G Williams; Edith Jasny; Michael Piatak; Jeffrey D Lifson; Andres M Salazar; James L Blanchard; Agegnehu Gettie; Melissa Robbiani Journal: PLoS One Date: 2010-09-21 Impact factor: 3.240